Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

It's been an excellent year for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech company. Viking Therapeutics' leading candidate, VK2735, is a potential GLP-1 weight loss medicine. It reported ...

One could be forgiven for feeling the same way about the current world of drug delivery devices, with an increasingly ...

We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

One billionaire investor whom investors of all sizes follow closely is Philippe Laffont of Coatue Management. Known for ...

According to GoodRx, compliance rates are high, with only 9% of commercially insured people having full Zepbound coverage and 14% having full Wegovy coverage. This refers to insurance coverage that ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

The GLP-1 receptor agonists work by mimicking the GLP-1 hormone in the gut, and the dual agonists work by mimicking both the GLP-1 and GIP hormones, which regulate blood glucose and appetite.In most ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.